Formestane (4-hydroxyandrostenedione) (Lentaron – Ciba) is the first of a new class of drugs that selectively inhibit aromatase, the enzyme that converts androgens to oestrogens. It is licensed for the treatment of postmenopausal women with advanced breast cancer and has been promoted by the manufacturer as offering new hope for those who have relapsed on tamoxifen.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.